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Abstract
Background: DNAzymes are DNA molecules that can directly cleave cognate mRNA, and have been developed to silence
gene expression for research and clinical purposes. The advantage of DNAzymes over ribozymes is that they are inexpensive
to produce and exhibit good stability. The ‘‘10-23 DNA enzyme’’ is composed of a catalytic domain of 15 deoxynucleotides,
flanked by two substrate-recognition domains of approximately eight nucleotides in each direction, which provides the
complementary sequence required for specific binding to RNA substrates. However, these eight nucleotides might not
afford sufficient binding energy to hold the RNA substrate along with the DNAzyme, which would interfere with the
efficiency of the DNAzyme or cause side effects, such as the cleavage of non-cognate mRNAs.
Methodology: In this study, we inserted a nonpairing bulge at the 59 end of the ‘‘10–23 DNA enzyme’’ to enhance its
efficiency and specificity. Different sizes of bulges were inserted at different positions in the 59 end of the DNAzyme. The
non-matching bulge will avoid strong binding between the DNAzyme and target mRNA, which may interfere with the
efficiency of the DNAzyme.
Conclusions: Our novel DNAzyme constructs could efficiently silence the expression of target genes, proving a powerful
tool for gene silencing. The results showed that the six oligo bulge was the most effective when the six oligo bulge was 12–
15 bp away from the core catalytic domain.
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Introduction
At least four different approaches have been used for gene
silencing to date, these include: gene knockout by homologous
recombination [1]; antisense inhibition by the use of synthetic
oligonucleotides that hybridize with DNA or RNA [2,3,4];
cleavage of target mRNA by ribozymes or DNAzymes [5]; and
RNA interference by inducing the endogenous siRNA process
pathway [6,7]. Studies by Paterson et al. (1977) demonstrated that
gene expression could be modified through the use of exogenous
nucleic acids that were complementary to target RNAs. Zamecnik
and Stephenson (1978) inhibited the replication of Rous sarcoma
virus by the use of a short antisense DNA oligonucleotide (ASON)
that was reverse complementary to a particular transcript of the
virus [8]. ASONs or ASON analogs are often employed for in vivo
antisense applications due to their stability and nuclease resistance
[9,10,11]. Generally, these molecules block gene expression by
hybridizing to the target mRNA, resulting in subsequent double-
helix formation which inhibits transcript processing or translation.
Furthermore, cellular RNases are able to bind to the DNA–RNA
duplex and hydrolyze the mRNA, resulting in increased mRNA
transcript degradation [12,13,14].
Breaker andJoyce (1994)madethe assumption that becauseRNA
and DNA are similar chemical compounds, DNA molecules with
enzymatic activity could also be developed as ribozymes. This
propositionledtothedevelopmentofaDNAenzymeidentifiedfrom
al i b r a r yo f.1,000 different DNA molecules by successive rounds of
in vitro selective amplification. The selected molecule was designated
the ‘‘10–23 DNA enzyme,’’ and was composed of a catalytic domain
of15deoxynucleotidesflankedbytwosubstrate-recognitiondomains
of ,8 nucleotides on each side [15,16,17]. The recognition
sequences provided the specificity for binding to target RNA
substratesandsuppliedthebindingenergyrequiredtoholdtheRNA
substrate with the DNAzyme [18,19]. Although DNAzymes are less
costly and more stable than ribozymes, they still encounter problems
such as stability, efficiency and specificity to target mRNAs [20,21].
Their complexes with RNA are less stable than the corresponding
RNA:RNA duplexes, hence, mismatches might be generated during
their interactions with non-target mRNAs, such as the mRNAs from
other members of a gene family, resulting in non-specific cleavage
[22,23,24,25].Inthisstudy,weintroducednewbulgestructureatthe
59 end of the ‘‘10–23’’ deoxyribozyme to enhance the efficiency and
specificity of the DNAzyme.
Results
Design and synthesis of ASON–Bulge–DNAzymes
In this study, we designed different sizes of bulges at different
positions at the 59 end of the regular DNAzyme. A non-matching
bulge will avoid strong binding between the DNAzyme and target
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Furthermore, the bulge structure would activate cellular RNases to
hydrolyze the mRNA, resulting in increased mRNA transcript
degradation. We introduced different sized oligo loops between
the DNAzyme core sequence and the ASON sequence (Figure 1).
ASON–Bulge–DNAzyme significantly reduced the
expression of eGFP
To assess the efficiency of the ASON–Bulge–DNAzyme
complex, the ASON–Bulge–DNAzymes were chemically synthe-
sized and co-transfected with pEGFP-C1 plasmid into BHK21
cells. As shown in Figure 2 (A, B and C), the ASON–Bulge–
DNAzymes exhibited a significant reduction in enhanced green
fluorescent protein (eGFP) expression compared with the regular
DNAzyme.
To examine whether the efficiency of the ASON–Bulge–
DNAzyme was site limited, we synthesized another ASON–
Bulge–DNAzyme targeting a different site, the eGFP mRNA. As
shown in Figure 2 (D and E), the new structure also exhibited
much higher efficiency than the regular DNAzyme. These results
demonstrated that the bulge-containing DNAzyme was more
effective in gene silencing compared with the regular DNAzyme.
The effect of size and position of the bulge on the
efficiency of gene silencing
To assess the inhibition effect of different bulge constructs, we
tested eGFP expression levels by a GFP fluorescence assay.
DNAzymes with three, six, nine and 12 oligo bulges were designed
and co-transfected with pEGFP-C1 plasmid into BHK21 cells.
The results showed that the six oligo bulge was the most effective
(Figure 3). Furthermore, the DNAzyme was most effective when
the six oligo bulge was located 12–15 bp away from the core
catalytic domain (Figure 4).
ASON–Bulge–DNAzyme inhibited the expression of eGFP
over a long time period
To quantitatively assess the inhibition effect of these constructs,
we tested eGFP expression levels at different time points by a GFP
fluorescence assay. The results further confirmed that the ASON–
Bulge structure could not only enhance the efficiency of the
DNAzyme, but could also sustain the inhibitory effect for longer
compared with the regular DNAzyme (Figure 5).
ASON–Bulge–DNAzyme decreased eGFP expression via
the mRNA degradation pathway
To test whether the ASON–Bulge–DNAzyme decreased eGFP
expression by virtue of the mRNA degradation pathway, a semi-
quantitative RT-PCR assay was employed to test the mRNA level
of eGFP. The results confirmed that the ASON–Bulge structure
could enhance the efficiency of the DNAzyme by decreasing the
eGFP mRNA level. Western blot analysis further confirmed the
efficiency of the ASON–Bulge–DNAzyme (Figure 6).
ASON–Bulge–DNAzyme significantly reduced the
expression of luciferase
To assess whether the ASON–Bulge–DNAzyme was gene
specific, we synthesized an ASON–Bulge–DNAzyme against
firefly luciferase. The results showed that this structure was more
effective than the regular DNAzyme (Figure 7).
ASON–DNAzyme was effective against, and specific to,
endogenous genes
To test whether the ASON–Bulge–DNAzyme was effective
against endogenous genes, we selected integrins as target
molecules. Integrins are a large family of heterodimeric trans-
membrane glycoproteins that attach cells to extracellular matrix
proteins of the basement membrane or to ligands on other cells.
There are many types of integrins on the cell surface relating to
different functions. We designed an ASON–Bulge–DNAzyme
against the endogenous integrin b1 (targeted sequence b1: 59-
GATTCTCCAGAAGGTGGTTTCGATGCCATCATGCAAG-
TTGCAGTTTGTGGATCACTGATT-39, b3: 59-GATGCCC-
CAGAGGGTGGCTTTGATGCCATCATGCAGGCTACAG-
TCTGTGATGAAAAGATT-39). The chemically synthesized
DNAzyme was used to transfect HepG2 cells. As shown in
Figure 8, the mRNA level of integrin b1 was significantly
decreased, while the mRNA level of integrin b3 was unchanged
compared with the regular DNAzyme. These results showed that
this structure not only enhanced the efficiency of the DNAzyme,
but also increased its specificity by minimizing the side effects, i.e.,
digestion of non-target mRNA.
Discussion
Although RNA interference is the most widely used tools for
gene silencing, The instablity, short half-life, inducing undesired
IFN responds and other drawbacks per se limits its application in
biology studies, clinical trials, and antivirus treatments
[26,27,28,29]. The advantage of DNAzymes over ribozymes is
that they are inexpensive to produce and inherently more stable
[30,31]. DNAzymes can be designed to cleave virtually any RNA
target by selecting appropriate flanking sequences [32,33]. The
recognition domains provide specificity and binding energy,
however, if the binding strength is too strong or too weak between
the DNAzyme and the substrate this can be antagonistic to
catalysis [34,35,36].
Figure 1. Schematic of the structure of ASON-Bulge-DNAzyme. A. Regular DNAzyme. B. ASON-Bulge-DNAzyme. A 15 base AS-ON was
inserted at the 59 end of ‘‘10-23’’deoxyribozyme to target the mRNA substrate and an unmatched loop between the DNAzyme sequence and ASON
sequence was designed.
doi:10.1371/journal.pone.0018629.g001
ASON-DNAzyme Complex
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ability to be targeted to the cell of interest, intracellular
localization, the ability to hybridize with the mRNA target, and
the ability to achieve a sufficient intracellular concentration while
avoiding interacting with non-target mRNAs [37,38]. Within
living cells, mRNA transcripts exist in secondary structures and
interact with cytoplasmic proteins, therefore, some of the mRNA
sequences are hidden and only partial sequences are accessible
[39]. mRNAs exist in several cellular compartments, including the
cytoplasm, nucleus and nucleolus. To suppress gene expression,
DNAzymes must be colocalized to the same intracellular
compartment as their target mRNA [40,41]. Antisense RNA
inserted within a variable region of ribosomal RNA (rRNA) has
been shown to enhance ribozyme efficiency due to colocalization
of rRNA with mRNA [42,43].
In this study, we introduced complementary oligonucleotides
(ASONs) at the 59 end of DNAzymes to enhance the specificity
of targeting to the mRNA substrate. To avoid too high a binding
strength between the DNAzyme and the target mRNA, we
introduced a nonpairing bulge structure into the DNAzyme. The
formation of a bulge structure ensured that the target mRNA
was easily hydrolyzed. Our results demonstrated that the
incorporation of an ASON and a mispairing bulge in the
DNAzyme conferred higher efficiency and specificity in gene
silencing.
Materials and Methods
Design and synthesis of the ASON–Bulge–DNAzyme
A 15 base ASON was inserted at the 59 end of the ‘‘10-23’’
deoxyribozyme. To avoid too high a binding strength between the
DNAzyme and the target mRNA which might interfere with
Figure 2. Transfection of ASON-Bulge-DNAzyme resulted in significantly reduced eGFP expression. BHK21 cells were co-transfected
with 0.5 mg pECFP-C1 plasmid and 0.25 mg of DNAzymes A. pEGFP control; B. Regular DNAzyme-1; C. ASON-Bulge-DNAzyme-1; D. Regular
DNAzyme-2; E.ASON-Bulge-DNAzyme-2. Calibration bar for A-E, 100 mm.
doi:10.1371/journal.pone.0018629.g002
Figure 3. The effect of different bulge size on DNAzyme
efficiency. Cells were cotransfected with 0.5 mg pECFP-C1 plasmid and
0.25 mg of DNAzymes. 1. pEGFP control; 2. Regular DNAzyme; 3. 3nt-
Bulge-DNAzyme; 4. 6nt-Bulge-DNAzyme; 5. 9nt-Bulge-DNAzyme; 6.
12nt-Bulge-DNAzyme. The error bars denote Standard deviation (SD).
doi:10.1371/journal.pone.0018629.g003
ASON-DNAzyme Complex
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of the DNAzyme. The oligonucleotides used for this were as follows:
Regular DNAzyme-1 against eGFP:
59-CTCAGGTAGGGCTAGCTACAACGAGGTTGTCGG-39
ASON-Bulge-DNAzyme-1 against eGFP:
59-TGCTCAGGGCGGACTGAAGTACCTCAGGTAGGG-
CTAGCTACAACGAGGTTGTCGG-39
Size of the bulge in the annealing arm complex of the
DNAzyme
Bulges of differing sizes were incorporated into the complex
using the following oligonucleotides:
The 3 nt Bulge–DNAzyme:
59-TGCTCAGGGCGGACTGTACCTCAGGTAGGGCTA-
GCTACAACGAGGTTGTCGG-39
The 6 nt Bulge–DNAzyme:
59-TGCTCAGGGCGGACTGAAGTACCTCAGGTAGGG-
CTAGCTACAACGAGGTTGTCGG-39
The 9 nt Bulge–DNAzyme:
59-TGCTCAGGGCGGACTGAAGCGATACCTCAGGTAG-
GGCTAGCTACAACGAGGTTGTCGG-39
The 12 nt Bulge–DNAzyme:
59-TGCTCAGGGCGGACTGAAGTGACGTTAACCTCAG-
GTAGGGCTAGCTACAACGAGGTTGTCGG-39
Position of the bulge in the annealing arm of the
DNAzyme
The position of the bulge in the complex was altered using the
following oligonucleotides:
1. Bulge–6 nt–DNAzyme:
59-TGCTCAGGGCGGACTGAAGTACCTCAAGGGCTAG-
CTACAACGAGGTTGTCGG-39
2. Bulge–9 nt–DNAzyme:
59-TGCTCAGGGCGGACTGAAGTACCTCAGGTAGGG-
CTAGCTACAACGAGGTTGTCGG-39
3. Bulge–12 nt–DNAzyme:
59-CTTGCTCAGGGCGGAAGTACGGTGCTCAGGTAGG-
GCTAGCTACAACGAGGTTGTCGG-39
4. Bulge–15 nt–DNAzyme:
59-TCTTTGCTCAGGGATCTACCTGGGTGCTCAGGTA-
GGGCTAGCTACAACGAGGTTGTCGG-39
DNAzymes against Luciferase were constructed using the
following oligonucleotides:
Regular DNAzyme against Luciferase:
59-AGCATCGAGAGGCTAGCTACAACGACCGTTGT-39
ASON–Bulge–DNAzyme against Luciferase:
59-GGGCAATTTACCACGAGCAATAGCATCGAGAGGC-
TAGCTACAACGACCGTTGT-39.
DNAzymes against integrin b1 were constructed using the
following oligonucleotides:
Regular DNAzyme against integrin b1:
59-TTGCATGAGGCTAGCTACAACGAGGCATCG-39
ASON–Bulge–DNAzyme against integrin b1:
59-GTGATCCACAAACTGCAAGTACAACTTGCATGAG-
GCTAGCTACAACGAGGCATCG-39
Semi-quantitative RT-PCR analysis of eGFP
Two pairs of specific primers were designed according to the
sequence of the eGFP gene and the b-actin gene. The primers
were synthesized by Shanghai Generay Biotech Co., Ltd
(China).
eGFP-F1: 59-CTGGACGGCGACGTAAACGG-39
eGFP-R1: 59-CACGAACTCCAGCAGGACCAT-39
b-actin-F1: 59-GGCTCCGGCATGTGCAAGGC-39
b-actin-R1: 59-GAAGGTAGTTTCGTGGATGCC-39
Figure 5. Quantitative assessment of the silencing efficiency of
ASON-Bulge-DNAzyme by GFP fluorescence assay. BHK21 cells
wereharvestedandlysedin200 mllysisbuffer(0.1 MTris-HCl,0.1%Triton
X-100, 2 mM EDTA, pH 7.8). Thefluorescence of eGFP was measured
using a luminometer. The error bars denote Standard deviation (SD).
doi:10.1371/journal.pone.0018629.g005
Figure 4. The effect of different bulge positions on DNAzyme
efficiency. Cells were co-transfected with 0.5 mg pECFP-C1 plasmid and
0.25 mg of DNAzymes. 1. pEGFP control; 2. Regular DNAzyme; 3. 6nt; 4.
9nt; 5. 12nte; 6.15 nt. The error bars denote Standard deviation (SD).
doi:10.1371/journal.pone.0018629.g004
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56reverse transcriptase buffer, 1 ml of 10 mM dNTPs, 1 mlo f
eGFP-R1 primer (10 mM), 1 mlo fb-actin-R1 primer (10 mM), 1 ml
of RNase inhibitor (20 U/ml), 1 ml of MMLV reverse transcriptase
(5 U/ml) and 7 ml of RNase-free H2O in a total volume of 20 ml for
1 h at 42uC. The PCR conditions were as follows: 1 cycle at 94uC
for 5 min; followed by 30 cycles of 30 s at 94uC, 30 s at 55uC and
60 s at 72uC. A final elongation step of 10 min at 72uC was
included.
Semi-quantitative RT-PCR analysis of integrin genes
Two pairs of specific primers were designed according to the
sequence of the integrin b1 gene and the integrin b3 gene. The
primers were synthesized by Shanghai Generay Biotech Co.,
Ltd.
Integrin b1-F1: 59-ATCCCAGAGGCTCCAAAGATAT-39
Integrin b1-R1: 59-CACCAAGTTTCCCATCTCCAG-39
Integrin b3-F1: 59-AGGATTACCCTGTGGACATC-39
Integrin b3-R1: 59-CCGTGATCTTGCCAAAGTCAC-39
cDNA was synthesized using 4 ml of the total RNA, 4 mlo f
56reverse transcriptase buffer, 1 ml of 10 mM dNTPs, 1 mlo f
integrin b1-R1 primer (10 mM), 1 ml of integrin b3-R1 primer
(10 mM), 1 ml of RNase inhibitor (20 U/ml), 1 ml of MMLV
reverse transcriptase (5 U/ml) and 6 ml of RNase-free H2Oi na
total volume of 20 ml for 1 h at 42uC. The PCR conditions were as
follows: 1 cycle at 94uC for 5 min; followed by 35 cycles of 40 s at
94uC, 30 s at 55uC and 60 s at 72uC. A final elongation step of
10 min at 72uC was included.
Cell culture and transfection
BHK-21 cells (from ATCC) were cultured in Dulbecco’s
modified Eagle’s medium (DMEM; GIBCO, USA) containing
10% fetal bovine serum (FBS) supplemented with 1% penicillin–
streptomycin (GIBCO). Cells were cultured in 24-well plates and
transfected by Lipofectamine 2000 (Invitrogen, USA). The ratio of
DNAzyme to Lipofectamine was 1 mg:2 ml. Cells were co-
transfected with 0.5 mg of pECFP-C1 plasmid and 0.25 mgo f
siRNA expression cassettes in each well.
Western blot analysis
BHK-21 cells were harvested 36 h after eGFP DNAzyme
transfection. They were then washed with PBS three times, and
lysed with 100 ml of lysis buffer. Total cellular protein was
determined using the BioRad Protein Assay reagent (Bio-Rad
Laboratories). The eGFP was detected using mouse anti-GFP
Figure 6. Semi-quantitative RT-PCR and Western blot analysis of the mechanism of ASONBulge-DNAzyme. A. RT-PCR of eGFP. B. RT-
PCR of b-actin. C. Western blot of eGFP.
doi:10.1371/journal.pone.0018629.g006
Figure 7. Quantitative assessment of the silencing efficiency of
ASON-Bulge-DNAzyme against luciferase. BHK21 cells were
harvested and lysed by in 200 ml lysis buffer (0.1 M Tris-HCl, 0.1%
Triton X-100, 2 mM EDTA, pH 7.8). The luciferase activity was measured
using a luminometer. The error bars denote Standard deviation (SD).
doi:10.1371/journal.pone.0018629.g007
ASON-DNAzyme Complex
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Plus (Amersham Biosciences).
Reporter gene assay
BHK-21 cells were harvested and lysed with 200 ml of lysis
buffer (0.1 M Tris, 0.1% Triton X-100, 2 mM EDTA, pH 7.8).
The eGFP fluorescence was analyzed using a luminometer
(Modulus, Turner Biosystems, USA).
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